Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion Pharma's gross profit for the
three
months ended in Mar. 2026 was BDT626 Mil. Orion Pharma's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1,424 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Orion Pharma's gross profit for the
three
months ended in Mar. 2026 was BDT626 Mil. Orion Pharma's Revenue for the
three
months ended in Mar. 2026 was BDT1,487 Mil. Therefore, Orion Pharma's Gross Margin % for the quarter that ended in Mar. 2026 was 42.09%.
Orion Pharma had a gross margin of 42.09% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 12 years, the highestGross Margin % of Orion Pharma was 37.89%. The lowest was 16.37%. And the median was 25.32%.
Warning Sign:
Orion Pharma Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.9%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orion Pharma had a gross margin of 42.09% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Orion Pharma Gross Profit Related Terms
Orion Pharma Gross Profit Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Gross Profit Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Gross Profit vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1,424 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orion Pharma (DHA:ORIONPHARM) has a Gross Profit of BDT1,424 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Gross Profit too high?
Orion Pharma's current Gross Profit is BDT1,424 Mil. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Gross Profit compare to CEG and VST?
Orion Pharma's Gross Profit of BDT1,424 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for an Utilities - Independent Power Producers company?
A good Gross Profit depends on the Utilities - Independent Power Producers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Orion Pharma and its competitors. Orion Pharma's current Gross Profit is BDT1,424 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT19.82, compared to a current price of BDT28.60 — trading 44.3% above its estimated fair value. The current Gross Profit is BDT1,424 Mil. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Gross Profit is BDT1,424 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.60 is trading 44.3% above its estimated GF Value™ of BDT19.82.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Gross Profit: BDT1,424 Mil
GF Value™: BDT19.82 vs. price of BDT28.60 (44.3% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
